AngioDynamics (ANGO) Margins Stay Negative In Q2 2026 And Test Bullish Turnaround Hopes

AngioDynamics (ANGO) just posted another unprofitable quarter, reporting Q2 2026 revenue of US$79.4 million, a basic EPS loss of US$0.15, and net income loss of US$6.35 million, against a trailing twelve month revenue base of US$307.3 million and a loss of US$27.71 million. Over recent quarters the company has reported revenue of US$72.8 million in Q2 2025, US$72.0 million in Q3 2025, US$80.2 million in Q4 2025, US$75.7 million in Q1 2026, and US$79.4 million in Q2 2026. Quarterly EPS losses ranged between US$0.11 and US$0.31 over the same period, so the latest results keep attention on how quickly margins can be repaired rather than expanded.

See our full analysis for AngioDynamics.

With the headline results on the table, the next step is to see how these margin pressures and revenue trends line up against the main narratives investors follow around AngioDynamics and where the fresh numbers may challenge those stories.

See what the community is saying about AngioDynamics

TTM losses of US$27.7 million keep profitability in focus

• On a trailing twelve month basis, AngioDynamics generated US$307.3 million of revenue and a net loss of US$27.71 million, with basic EPS of US$0.67 loss, which keeps attention on how far the business still is from break even.
• Consensus narrative expects earnings to reach US$11.0 million by about 2028, yet the trailing net loss of US$27.71 million and recent quarterly losses between US$4.4 million and US$12.8 million highlight how much turnround is still required to match that view.
  • Analysts are assuming margins move from 11.6% loss today to 3.1% profit, while the last six quarters of net income show consistent losses, so recent history leans against a quick shift into the black.
  • The consensus price target of US$19.33 sits above the current US$10.31 share price, and the current loss profile means investors need to be comfortable with that earnings ramp assumption to agree with the target.

Price to sales of 1.4x versus peers at 8.7x

• The shares trade on a P/S of 1.4x, compared with a peer average of 8.7x and a US Medical Equipment industry average of 2.6x, so the stock sits at a lower sales multiple than many names in its space.
• Supporters of the bullish view argue that differentiated Med Tech platforms can justify higher valuations over time. However, the modest 4.9% trailing revenue growth and unprofitable TTM earnings mean the current low P/S also lines up with cautious market expectations.
  • Bullish assumptions look for revenue growth of 7.1% a year and earnings of US$12.3 million by 2028, which would contrast sharply with the current TTM loss of US$27.71 million if achieved.
  • To match the bullish analyst target, investors would need to accept a P/E of 96.9x on those future earnings, while today there is no positive EPS to support a standard P/E comparison.

On these numbers, bulls see a Med Tech growth story that the current P/S does not fully reflect, while the earnings track record invites closer scrutiny before leaning too hard into that optimism. 🐂 AngioDynamics Bull Case

Five year 12.4% annual loss growth backs cautious views

• Over the past five years, losses have grown at about 12.4% per year and earnings are not forecast to become profitable within the next three years, which lines up with the TTM net loss of US$27.71 million and continued quarterly EPS losses.
• Skeptics point out that even with 4.9% annual revenue growth, the pattern of widening losses and ongoing adjusted loss guidance in fiscal 2026 fits the bearish concern that margin improvement could be slower or more limited than some forecasts assume.
  • The bearish narrative still uses a 7.1% revenue growth rate and margins reaching 3.4% profit by 2028, but the current run rate of quarterly losses between US$4.4 million and US$12.8 million underlines the gap between today and that outcome.
  • With no quantified reward drivers in the trailing data set and no path to profitability within three years in the risk summary, the historical 12.4% annual loss growth is a key figure bears rely on when they question how quickly earnings can improve.

For investors weighing that cautious stance, the latest figures give clear data points to stress test any expectation that earnings can move from multi year losses into sustained profit. 🐻 AngioDynamics Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AngioDynamics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mixed tone of these results and narratives, it makes sense to review the underlying data yourself and stress test the assumptions that matter to you. Before deciding what the latest quarter means for your thesis, take a moment to look at the company's 2 important warning signs.

See What Else Is Out There

Ongoing multi year losses, no near term path to profitability and reliance on optimistic earnings ramps all point to elevated business and earnings risk for AngioDynamics.

If that risk profile feels uncomfortable, it is worth comparing this setup with companies screened for steadier fundamentals by checking out the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com